Late-Breaking Science to headline Scientific Sessions

The lineup of planned Late-Breaking Science is stronger this year than ever before. Here are the nine featured late-breaking science presentations. Check the Online Program Planner for times and dates of the presentations.

LBS.01: Heart Failure and Atrial Fibrillation: Vitamins, Minerals, Nutrients and More

• Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) Trial — GALACTIC-HF
• Ferric Carboxymaltose in Iron Deficient Patients Admitted for Acute Heart Failure — AFFIRM-AHF
• The Vital Rhythm Trial: Omega-3 Fatty Acid and Vitamin D Supplementation in the Primary Prevention of Atrial Fibrillation — VITAL Rhythm

LBS. 02: Bending the Curve for CV Disease — Precision or PolyPill?

• A Polypill for Primary Prevention of Cardiovascular Disease in Intermediate Risk People: Results of the International Polycap Study (TIPS)-3 — TIPS-3
• Aspirin Alone and in Combination With a Polypill in Cardiovascular Disease Primary Prevention: Results From the International Polycap Study (TIPS)-3 — TIPS-3
• Prevalence and Prediction of Coronary Artery Disease in the General Population — Results From the Swedish Cardiopulmonary Bioimage Study (scapis) — SCAPIS

LBS.03: Current Challenges in Coronary and Valve Disease

• Ticagrelor Versus Clopidogrel in Elective Percutaneous Coronary Intervention: The Alpheus Trial — ALPHEUS
• Coronary OCT and Cardiac MRI to Determine Underlying Causes of MINOCA in Women — HARP — Women’s Heart Attack Research Program

LBS.04: Fish Oil, Fancy Drugs and Frustrations in Lipid Management

• STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) in Patients With High Vascular Risk and Atherogenic Dyslipidemia — STRENGTH
• Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in the Elderly: Results of the Omemi Trial — OMEMI 
• A Three-Arm N-of-1 Trial With Statin, Placebo and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial — SAMSON
• The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

LBS.05: Stents, Valves and Clots

• A Prospective Multicenter Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System in Patients With Stable or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results of the PIONEER III Trial — PIONEER III
• One-Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug Eluting Stent Implantation — One-Month DAPT trial
• Rivaroxaban Versus Warfarin in Patients With Bioprosthetic Mitral Valves and Atrial Fibrillation or Flutter: Primary Results From the RIVER Randomized Trial — RIVER Trial

LBS.06: To Screen or Not to Screen, and Then What?  Studies of Detection and Treatment of AF

• Enhanced Monitoring for Atrial Fibrillation Following Cardiac Surgery: Primary Results of The SEARCH-AF Cardiolink Randomized Trial — SEARCH-AF
• Screening for Atrial Fibrillation in Older Adults at Primary Care Visits Using Single Lead Electrocardiograms: The VITAL-AF Trial — VITAL-AF
• 3-Year Clinical Outcomes in a Nationwide, Randomized, Pragmatic Clinical Trial of Atrial Fibrillation Screening — Mhealth Screening to Prevent Strokes (mstops) — mSToPS
• Early Invasive Intervention for Atrial Fibrillation — EARLY-AF

LBS.07: Randomized Trials — Brain, Kidney and Heart

• Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes — FIDELIO-DKD
• Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Tia of Atherosclerotic Origin —THALES
• RHAPSODY: Rilonacept an IL-1α and IL-1β Trap Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients With Recurrent Pericarditis — RHAPSODY
• Rapid Assessment of Potential Ischemic Heart Disease With CTCA: The Rapid-CTCA Trial. A Randomized Trial of CTCA in the Evaluation, Intervention and Outcome of Adults With Suspected or Confirmed Acute Coronary Syndrome Presenting to the Emergency Department — RAPID-CTCA
• SOLOIST-WHF: Sotagliflozin in Diabetes Patients with Recent Worsening Heart Failure – SOLOIST-WHF
• SCORED: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – SCORED

LBS.08: AHA Goes Viral: COVID-19, Influenza Vaccines and Cardiovascular Disease

• The AHA COVID-19 Cardiovascular Disease Registry: Design, Implementation and Initial Results
• Racial and Ethnic Differences in Treatment and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association COVID-19 Cardiovascular Disease Registry
• Association of Body Mass Index With Death, Mechanical Ventilation and Cardiovascular Outcomes in COVID-19: Findings From the AHA COVID-19 Cardiovascular Disease Registry
• Impact of Cardiovascular Disease on Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across the United States
• High Dose Versus Standard Dose Influenza Vaccine in Patients With High Risk Cardiovascular Disease: Results From the Invested Trial — INVESTED

LBS.09: High Tech or High Touch: Creative Strategies to Optimize Patient Care

• An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial — EPIC-HF
• My Recorded On-Demand Audio Discharge Instructions (MyRoad) In Heart Failure — MYROAD
• Digital Care Transformation: One-Year Report of >5,000 Patients Enrolled in a Remote Algorithm-Based CV Risk Management Program to Achieve Optimal Lipid and Hypertension Control
• Group Medical Visits and Microfinance for Patients With Diabetes and Hypertension in Western Kenya: Results of the BIGPIC Trial — BIGPIC